Given the large stake in the stock by institutions, Nektar Therapeutics' stock price might be vulnerable to their trading decisions The top 11 shareholders own 52% of the company Every investor in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback